Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formul...
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT00372775
- Locations
- 🇪🇸
Pfizer Investigational Site, Valencia, Spain
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00357318
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00338884
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT00329043
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1943
- Registration Number
- NCT00326898
- Locations
- 🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸Mount Carmel Health Center West, Columbus, Ohio, United States
🇺🇸MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States
Study of SU11248 in Men With Advanced Prostate Cancer
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT00299741
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel-Deaconess Medical Center, Boston, Massachusetts, United States
A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone
- Conditions
- Interventions
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 162
- Registration Number
- NCT00265317
- Locations
- 🇪🇸
Pfizer Investigational Site, Santander, Cantabria, Spain
An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 78
- Registration Number
- NCT00226811
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-06-09
- Last Posted Date
- 2010-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT00113516
- Locations
- 🇫🇷
Pfizer Investigational Site, Villejuif, France
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 111
- Registration Number
- NCT00092001
- Locations
- 🇪🇸
Pfizer Investigational Site, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.